**Boniva** is a bisphosphonate that inhibits osteoclast-mediated bone resorption, reducing bone turnover, thus leading to an average net gain in bone mass

**Pre-Authorization Criteria:** Prevention or treatment of osteoporosis in postmenopausal women when unable to tolerate or failed treatment with alendronate or risendronate.

Off-Label Uses: hypercalcemia of malignancy; treatment to reduce bone pain and skeletal complications from metastatic bone disease due to breast cancer. (See VCHCP policy on Coverage of Prescription Medication for Off-Label Use.)

**Dosing:** One 150mg tablet taken once monthly on the same date each month

**PRECAUTIONS:** gastrointestinal irritation; hypocalcemia; musculoskeletal pain; post dental extraction osteonecrosis; occult atypical fractures of the femur

**Note:** 1) All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically. 2) Treat hypocalcemia and other disturbances of bone and mineral metabolism before starting BONIVA therapy. Instruct patients to take supplemental calcium and vitamin D if their dietary intake is inadequate. 3) Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture.
**DRUG INTERACTIONS:** increased risk and/or severity of gastrointestinal irritation with concomitant use of aspirin/NSAIDS or other medications which may cause GI upset; calcium, magnesium or iron supplements interfere with absorption of Boniva (take with an interval of 1-2 hours);

**REFERENCES**


**Revision History:**

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 2/5/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>